Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Breast cancer risk reduction: Notable achievements and remaining challenges.

Vogel VG.

Breast J. 2020 Jan;26(1):86-91. doi: 10.1111/tbj.13717.

PMID:
31971344
2.

Relationships of self-perceived age with geriatric assessment domains in older adults with cancer.

Loh KP, Duberstein P, Zittel J, Lei L, Culakova E, Xu H, Plumb S, Flannery MA, Magnuson A, Bautista J, Wittink M, Gilmore N, Targia V, Conlin A, Berenberg J, Vogel VG, Mohile SG.

J Geriatr Oncol. 2019 Dec 30. pii: S1879-4068(19)30495-3. doi: 10.1016/j.jgo.2019.12.011. [Epub ahead of print]

PMID:
31899198
3.

Exome Sequencing-Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants.

Manickam K, Buchanan AH, Schwartz MLB, Hallquist MLG, Williams JL, Rahm AK, Rocha H, Savatt JM, Evans AE, Butry LM, Lazzeri AL, Lindbuchler DM, Flansburg CN, Leeming R, Vogel VG, Lebo MS, Mason-Suares HM, Hoskinson DC, Abul-Husn NS, Dewey FE, Overton JD, Reid JG, Baras A, Willard HF, McCormick CZ, Krishnamurthy SB, Hartzel DN, Kost KA, Lavage DR, Sturm AC, Frisbie LR, Person TN, Metpally RP, Giovanni MA, Lowry LE, Leader JB, Ritchie MD, Carey DJ, Justice AE, Kirchner HL, Faucett WA, Williams MS, Ledbetter DH, Murray MF.

JAMA Netw Open. 2018 Sep 7;1(5):e182140. doi: 10.1001/jamanetworkopen.2018.2140.

4.

Early cancer diagnoses through BRCA1/2 screening of unselected adult biobank participants.

Buchanan AH, Manickam K, Meyer MN, Wagner JK, Hallquist MLG, Williams JL, Rahm AK, Williams MS, Chen ZE, Shah CK, Garg TK, Lazzeri AL, Schwartz MLB, Lindbuchler DM, Fan AL, Leeming R, Servano PO 3rd, Smith AL, Vogel VG, Abul-Husn NS, Dewey FE, Lebo MS, Mason-Suares HM, Ritchie MD, Davis FD, Carey DJ, Feinberg DT, Faucett WA, Ledbetter DH, Murray MF.

Genet Med. 2018 Apr;20(5):554-558. doi: 10.1038/gim.2017.145. Epub 2017 Oct 26.

5.

The Burdens and Uncertainties of Doing What One Should Do.

Vogel VG.

Cancer Prev Res (Phila). 2017 Jul 24. doi: 10.1158/1940-6207.CAPR-17-0173. [Epub ahead of print]

PMID:
28739585
6.
7.

Breast cancer chemoprevention: the saga of underuse continues.

Wickerham DL, Vogel VG.

J Natl Cancer Inst. 2014 Dec 3;107(1):399. doi: 10.1093/jnci/dju399. Print 2015 Jan. No abstract available.

PMID:
25475565
8.

Role of hormones in cancer prevention.

Vogel VG.

Am Soc Clin Oncol Educ Book. 2014:34-40. doi: 10.14694/EdBook_AM.2014.34.34. Review.

9.

Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.

Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Morrow M, Parker B, Runowicz C, Vogel VG 3rd, Wade JL, Lippman SM.

J Clin Oncol. 2013 Aug 10;31(23):2942-62. doi: 10.1200/JCO.2013.49.3122. Epub 2013 Jul 8. Review. Erratum in: J Clin Oncol. 2013 Dec 1;31(34):4383.

PMID:
23835710
10.

Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention.

Ingle JN, Liu M, Wickerham DL, Schaid DJ, Wang L, Mushiroda T, Kubo M, Costantino JP, Vogel VG, Paik S, Goetz MP, Ames MM, Jenkins GD, Batzler A, Carlson EE, Flockhart DA, Wolmark N, Nakamura Y, Weinshilboum RM.

Cancer Discov. 2013 Jul;3(7):812-25. doi: 10.1158/2159-8290.CD-13-0038. Epub 2013 Jun 13.

11.

Erythrocyte omega-6 and omega-3 fatty acids and mammographic breast density.

Hudson AG, Reeves KW, Modugno F, Wilson JW, Evans RW, Vogel VG, Gierach GL, Simpson J, Weissfeld JL.

Nutr Cancer. 2013;65(3):410-6. doi: 10.1080/01635581.2013.760744.

12.

Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.

Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE; American Society of Clinical Oncology.

J Clin Oncol. 2013 Mar 1;31(7):961-5. doi: 10.1200/JCO.2012.45.9859. Epub 2012 Nov 5. Review.

PMID:
23129741
13.

Urinary estrogen metabolites and breast cancer: a combined analysis of individual level data.

Dallal CM, Stone RA, Cauley JA, Ness RB, Vogel VG, Fentiman IS, Fowke JH, Krogh V, Loft S, Meilahn EN, Muti P, Olsen A, Overvad K, Sieri S, TjĂžnneland A, Ursin G, Wellejus A, Taioli E.

Int J Biol Markers. 2013 Apr 23;28(1):3-16. doi: 10.5301/JBM.2012.9353.

PMID:
22865302
14.

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.

Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, Cronin MT, Watson D, Shak S, Bohn OL, Fumagalli D, Taniyama Y, Lee A, Reilly ML, Vogel VG, McCaskill-Stevens W, Ford LG, Geyer CE Jr, Wickerham DL, Wolmark N, Paik S.

J Clin Oncol. 2011 Nov 1;29(31):4160-7. doi: 10.1200/JCO.2010.32.9615. Epub 2011 Sep 26.

15.

Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.

Goetz MP, Schaid DJ, Wickerham DL, Safgren S, Mushiroda T, Kubo M, Batzler A, Costantino JP, Vogel VG, Paik S, Carlson EE, Flockhart DA, Wolmark N, Nakamura Y, Weinshilboum RM, Ingle JN, Ames MM.

Clin Cancer Res. 2011 Nov 1;17(21):6944-51. doi: 10.1158/1078-0432.CCR-11-0860. Epub 2011 Aug 31. Erratum in: Clin Cancer Res. 2012 Jun 15;18(12):3491.

16.

Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).

Runowicz CD, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Ford LG, Vogel VG, Wolmark N.

Am J Obstet Gynecol. 2011 Dec;205(6):535.e1-5. doi: 10.1016/j.ajog.2011.06.067. Epub 2011 Jun 24.

17.

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.

Freedman AN, Yu B, Gail MH, Costantino JP, Graubard BI, Vogel VG, Anderson GL, McCaskill-Stevens W.

J Clin Oncol. 2011 Jun 10;29(17):2327-33. doi: 10.1200/JCO.2010.33.0258. Epub 2011 May 2. Erratum in: J Clin Oncol. 2013 Nov 10;31(32):4167.

18.

A method to estimate off-schedule observations in a longitudinal study.

Reeves KW, Stone RA, Modugno F, Ness RB, Vogel VG, Weissfeld JL, Habel LA, Vuga M, Cauley JA.

Ann Epidemiol. 2011 Apr;21(4):297-303. doi: 10.1016/j.annepidem.2010.11.013.

19.

Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial.

Ganz PA, Land SR, Geyer CE Jr, Cecchini RS, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff JA, Vogel VG, Erban JK, Livingston RB, Perez EA, Mamounas EP, Wolmark N, Swain SM.

J Clin Oncol. 2011 Mar 20;29(9):1110-6. doi: 10.1200/JCO.2010.29.7689. Epub 2011 Feb 7.

20.

Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women.

Vogel VG.

Breast Cancer (Dove Med Press). 2011 Oct 20;3:127-37. doi: 10.2147/BCTT.S11288. Review.

21.

Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.

Vogel VG.

Curr Drug Targets. 2011 Dec;12(13):1874-87. Review.

PMID:
21158712
22.

Nucleotide excision repair deficiency is intrinsic in sporadic stage I breast cancer.

Latimer JJ, Johnson JM, Kelly CM, Miles TD, Beaudry-Rodgers KA, Lalanne NA, Vogel VG, Kanbour-Shakir A, Kelley JL, Johnson RR, Grant SG.

Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21725-30. doi: 10.1073/pnas.0914772107. Epub 2010 Nov 30.

23.

Tipping the balance for the primary prevention of breast cancer.

Vogel VG.

J Natl Cancer Inst. 2010 Nov 17;102(22):1683-5. doi: 10.1093/jnci/djq435. Epub 2010 Nov 4. No abstract available.

PMID:
21051657
24.

Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.

Vogel VG, Costantino JP, Wickerham DL, McCaskill-Stevens W, Clarfeld RB, Grant MD, Wolmark N.

J Natl Cancer Inst Monogr. 2010;2010(41):181-6. doi: 10.1093/jncimonographs/lgq041. Review.

26.

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land SR, Ganz PA, Wolmark N.

N Engl J Med. 2010 Jun 3;362(22):2053-65. doi: 10.1056/NEJMoa0909638.

27.

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project.

Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076. Epub 2010 Apr 19.

28.

Altering the propensity for density: the benefits and risks of selective estrogen receptor modulators.

Vogel VG.

Menopause. 2009 Nov-Dec;16(6):1079-82. doi: 10.1097/gme.0b013e3181bc1c84. No abstract available.

PMID:
19779314
29.

Urinary estrogen metabolites in women at high risk for breast cancer.

Im A, Vogel VG, Ahrendt G, Lloyd S, Ragin C, Garte S, Taioli E.

Carcinogenesis. 2009 Sep;30(9):1532-5. doi: 10.1093/carcin/bgp139. Epub 2009 Jun 5.

30.

American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.

Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM; American Society of Clinical Oncology.

J Clin Oncol. 2009 Jul 1;27(19):3235-58. doi: 10.1200/JCO.2008.20.5179. Epub 2009 May 26.

31.

Incidence of invasive breast cancer in postmenopausal women after discontinuation of long-term raloxifene administration.

Vogel VG, Qu Y, Wong M, Mitchell B, Mershon JL.

Clin Breast Cancer. 2009 Feb;9(1):45-50. doi: 10.3816/CBC.2009.n.008.

PMID:
19299240
32.

The use of tamoxifen and raloxifene for the prevention of breast cancer.

Wickerham DL, Costantino JP, Vogel VG, Cronin WM, Cecchini RS, Ford LG, Wolmark N.

Recent Results Cancer Res. 2009;181:113-9. Review.

33.

The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.

Vogel VG.

Expert Rev Anticancer Ther. 2009 Jan;9(1):51-60. doi: 10.1586/14737140.9.1.51. Review. Erratum in: Expert Rev Anticancer Ther. 2009 Mar;9(3):388.

34.

American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment.

Zon RT, Goss E, Vogel VG, Chlebowski RT, Jatoi I, Robson ME, Wollins DS, Garber JE, Brown P, Kramer BS; American Society of Clinical Oncology.

J Clin Oncol. 2009 Feb 20;27(6):986-93. doi: 10.1200/JCO.2008.16.3691. Epub 2008 Dec 15.

35.

Longitudinal association of anthropometry with mammographic breast density in the Study of Women's Health Across the Nation.

Reeves KW, Stone RA, Modugno F, Ness RB, Vogel VG, Weissfeld JL, Habel LA, Sternfeld B, Cauley JA.

Int J Cancer. 2009 Mar 1;124(5):1169-77. doi: 10.1002/ijc.23996.

36.

Vascular endothelial growth factor and breast cancer risk.

Reeves KW, Ness RB, Stone RA, Weissfeld JL, Vogel VG, Powers RW, Modugno F, Cauley JA.

Cancer Causes Control. 2009 Apr;20(3):375-86. doi: 10.1007/s10552-008-9252-4. Epub 2008 Nov 6.

37.

Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer.

Vogel VG.

Menopause. 2008 Jul-Aug;15(4 Suppl):782-9. doi: 10.1097/gme.0b013e3181788d88. Review.

PMID:
18596599
38.

Managing the risk of breast cancer in postmenopausal women: introduction.

Vogel VG.

Menopause. 2008 Jul-Aug;15(4 Suppl):779-81. doi: 10.1097/gme.0b013e3181788d99. No abstract available.

PMID:
18596598
39.

Preventing breast cancer in high-risk women, 2008.

Vogel VG.

Oncology (Williston Park). 2008 May;22(6):666-73; discussion 679, 682, 684. Review.

40.

What do perceived cognitive problems reflect?

Bender CM, Pacella ML, Sereika SM, Brufsky AM, Vogel VG, Rastogi P, Casillo FE, Richey SM, Ryan CM.

J Support Oncol. 2008 May-Jun;6(5):238-42.

41.

Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.

Greenspan SL, Brufsky A, Lembersky BC, Bhattacharya R, Vujevich KT, Perera S, Sereika SM, Vogel VG.

J Clin Oncol. 2008 Jun 1;26(16):2644-52. doi: 10.1200/JCO.2007.15.2967. Epub 2008 Apr 21.

42.

Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women.

Hudson AG, Gierach GL, Modugno F, Simpson J, Wilson JW, Evans RW, Vogel VG, Weissfeld JL.

Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):680-7. doi: 10.1158/1055-9965.EPI-07-2739.

43.

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF, Robidoux A, Hoehn JL, Ingle JN, Geyer CE Jr, Costantino JP, Wolmark N.

J Clin Oncol. 2008 Apr 20;26(12):1965-71. doi: 10.1200/JCO.2007.14.0228. Epub 2008 Mar 10.

PMID:
18332472
44.

Breast cancer prevention.

Reeder JG, Vogel VG.

Cancer Treat Res. 2008;141:149-64. Review. No abstract available.

PMID:
18274088
45.

Breast cancer risk management.

Reeder JG, Vogel VG.

Clin Breast Cancer. 2007 Dec;7(11):833-40. doi: 10.3816/CBC.2007.n.047. Review.

PMID:
18269772
46.

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N.

J Clin Oncol. 2008 Feb 10;26(5):778-85. doi: 10.1200/JCO.2007.15.0235. Erratum in: J Clin Oncol. 2008 Jun 1;26(16):2793.

PMID:
18258986
48.

Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer.

Bender CM, Sereika SM, Brufsky AM, Ryan CM, Vogel VG, Rastogi P, Cohen SM, Casillo FE, Berga SL.

Menopause. 2007 Nov-Dec;14(6):995-8.

49.

Ontology, oncology, and preventive economies: developing drugs for cancer prevention.

Vogel VG.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5227-8. No abstract available.

50.

Chemoprevention strategies 2006.

Vogel VG.

Curr Treat Options Oncol. 2007 Feb;8(1):74-88. Review.

PMID:
17634835

Supplemental Content

Loading ...
Support Center